Skip to main content
Erschienen in: Drugs & Aging 2/2014

01.02.2014 | Review Article

The Association Between Drugs Frequently Used by the Elderly and Vitamin D Blood Levels: A Review of Observational and Experimental Studies

verfasst von: Anne Claire B. van Orten-Luiten, André Janse, Rosalie A. M. Dhonukshe-Rutten, Renger F. Witkamp

Erschienen in: Drugs & Aging | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The risk of adverse drug reactions (ADRs) rises with increasing age. In the field of ADRs, drug–nutrient interactions (DNIs) are a relatively unexplored area. More knowledge will contribute to the simple prevention of this type of ADR. As the prevalence of vitamin D deficiency in the elderly is high, the primary objective of this review is to evaluate the literature on the relationship between drug use and vitamin D status, focusing on medicines commonly used by the elderly. PubMed was searched for human epidemiological and clinical studies published until early 2013, investigating the relationship between vitamin D blood levels and use of drugs from one of the following groups: proton pump inhibitors (PPIs), biguanides, vitamin K antagonists, platelet aggregation inhibitors, thiazide diuretics, loop diuretics, beta-blocking agents, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II antagonists, statins, benzodiazepines, and antidepressants. A total of 63 publications were identified. Thiazide diuretics, statins, and calcium channel blocking agents were the most frequently studied drug groups. Associations between thiazides and vitamin D were mixed (n = 22), statins had no or positive associations (n = 16) and calcium blockers were not associated or were negatively associated with vitamin D (n = 10). In conclusion, several knowledge gaps exist on the relationship between drug use and vitamin D blood levels. Available data are scarce (particularly for the aged), study characteristics are highly variable, and found associations may be confounded by, amongst other things, the underlying disease. Nonetheless, this review provides a basis for future research on ADRs that contribute to nutrient deficiencies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. Arch Intern Med. 2010;170(13):1142–8.PubMedCrossRef Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. Arch Intern Med. 2010;170(13):1142–8.PubMedCrossRef
2.
Zurück zum Zitat van der Hooft CS, Dieleman JP, Siemes C, et al. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf. 2008;17(4):365–71.PubMedCrossRef van der Hooft CS, Dieleman JP, Siemes C, et al. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf. 2008;17(4):365–71.PubMedCrossRef
3.
Zurück zum Zitat Boullata JI, Hudson LM. Drug-nutrient interactions: a broad view with implications for practice. J Acad Nutr Diet. 2012;112(4):506–17.PubMedCrossRef Boullata JI, Hudson LM. Drug-nutrient interactions: a broad view with implications for practice. J Acad Nutr Diet. 2012;112(4):506–17.PubMedCrossRef
4.
Zurück zum Zitat Santos CA, Boullata JI. An approach to evaluating drug-nutrient interactions. Pharmacotherapy. 2005;25(12):1789–800.PubMedCrossRef Santos CA, Boullata JI. An approach to evaluating drug-nutrient interactions. Pharmacotherapy. 2005;25(12):1789–800.PubMedCrossRef
5.
Zurück zum Zitat Prentice A, Vitamin D. Deficiency: a global perspective. Nutr Rev. 2008;66(10 Suppl 2):S153–64.PubMedCrossRef Prentice A, Vitamin D. Deficiency: a global perspective. Nutr Rev. 2008;66(10 Suppl 2):S153–64.PubMedCrossRef
6.
Zurück zum Zitat Millen AE, Wactawski-Wende J, Pettinger M, et al. Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women’s Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr. 2010;91(5):1324–35.PubMedCrossRef Millen AE, Wactawski-Wende J, Pettinger M, et al. Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women’s Health Initiative Calcium plus Vitamin D clinical trial. Am J Clin Nutr. 2010;91(5):1324–35.PubMedCrossRef
7.
Zurück zum Zitat Murr C, Pilz S, Grammer TB, Kleber ME, et al. Vitamin D deficiency parallels inflammation and immune activation, the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chem Lab Med. 2012;50(12):2065–250. Murr C, Pilz S, Grammer TB, Kleber ME, et al. Vitamin D deficiency parallels inflammation and immune activation, the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chem Lab Med. 2012;50(12):2065–250.
8.
Zurück zum Zitat Robien K, Oppeneer SJ, Kelly JA, et al. Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract. 2013;10(28):194–208.CrossRef Robien K, Oppeneer SJ, Kelly JA, et al. Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract. 2013;10(28):194–208.CrossRef
10.
Zurück zum Zitat Sohl E, van Schoor NM, de Jongh RT, et al. The impact of medication on vitamin D status in older individuals. Eur J Endocrinol. 2012;166(3):477–85.PubMedCrossRef Sohl E, van Schoor NM, de Jongh RT, et al. The impact of medication on vitamin D status in older individuals. Eur J Endocrinol. 2012;166(3):477–85.PubMedCrossRef
11.
Zurück zum Zitat van Orten-Luiten ACB. Is use of medication associated with blood levels of micronutrients? A cross-sectional study of a Dutch geriatric hospital population [MSc]. Wageningen: Wageningen University; 2012. van Orten-Luiten ACB. Is use of medication associated with blood levels of micronutrients? A cross-sectional study of a Dutch geriatric hospital population [MSc]. Wageningen: Wageningen University; 2012.
12.
Zurück zum Zitat WHO Collaborating Centre for Drug Statistics Methodology of the Norwegian Institute of Public Health: The ATC/DDD system: The Anatomical Therapeutic Chemical classification system and the Defined Daily Dose. Oslo, Norway: Norwegian Institute of Public Health. Available from: http://www.whocc.no/. WHO Collaborating Centre for Drug Statistics Methodology of the Norwegian Institute of Public Health: The ATC/DDD system: The Anatomical Therapeutic Chemical classification system and the Defined Daily Dose. Oslo, Norway: Norwegian Institute of Public Health. Available from: http://​www.​whocc.​no/​.
13.
Zurück zum Zitat Avgeri M, Papadopoulou A, Platokouki H, et al. Assessment of bone mineral density and markers of bone turnover in children under long-term oral anticoagulant therapy. J Pediatr Hematol Oncol. 2008;30(8):592–7.PubMedCrossRef Avgeri M, Papadopoulou A, Platokouki H, et al. Assessment of bone mineral density and markers of bone turnover in children under long-term oral anticoagulant therapy. J Pediatr Hematol Oncol. 2008;30(8):592–7.PubMedCrossRef
14.
Zurück zum Zitat Seikaly MG, Quigley R, Baum M. Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia. Pediatr Nephrol. 2000;15(1–2):57–9.PubMedCrossRef Seikaly MG, Quigley R, Baum M. Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia. Pediatr Nephrol. 2000;15(1–2):57–9.PubMedCrossRef
15.
Zurück zum Zitat Riis B, Christiansen C. Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause. Metabolism. 1985;34(5):421–4.PubMedCrossRef Riis B, Christiansen C. Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause. Metabolism. 1985;34(5):421–4.PubMedCrossRef
16.
Zurück zum Zitat Sakhaee K, Nicar MJ, Glass K, et al. Reduction in intestinal calcium absorption by hydrochlorothiazide in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1984;59(6):1037–43.PubMedCrossRef Sakhaee K, Nicar MJ, Glass K, et al. Reduction in intestinal calcium absorption by hydrochlorothiazide in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1984;59(6):1037–43.PubMedCrossRef
17.
Zurück zum Zitat Manninen A, Wuorela H, Laippala P, et al. Intraplatelet free calcium and calcium-regulating hormones in plasma are not related to the antihypertensive effect of nifedipine in hypertensive pregnancy. Pharmacol Toxicol. 1995;77(5):327–32.PubMedCrossRef Manninen A, Wuorela H, Laippala P, et al. Intraplatelet free calcium and calcium-regulating hormones in plasma are not related to the antihypertensive effect of nifedipine in hypertensive pregnancy. Pharmacol Toxicol. 1995;77(5):327–32.PubMedCrossRef
18.
Zurück zum Zitat Rejnmark L, Vestergaard P, Heickendorff L, et al. Loop diuretics alter the diurnal rhythm of endogenous parathyroid hormone secretion. A randomized-controlled study on the effects of loop- and thiazide-diuretics on the diurnal rhythms of calcitropic hormones and biochemical bone markers in postmenopausal women. Eur J Clin Invest. 2001;31(9):764–72.PubMedCrossRef Rejnmark L, Vestergaard P, Heickendorff L, et al. Loop diuretics alter the diurnal rhythm of endogenous parathyroid hormone secretion. A randomized-controlled study on the effects of loop- and thiazide-diuretics on the diurnal rhythms of calcitropic hormones and biochemical bone markers in postmenopausal women. Eur J Clin Invest. 2001;31(9):764–72.PubMedCrossRef
19.
Zurück zum Zitat Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med. 1999;130(8):658–60.PubMedCrossRef Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med. 1999;130(8):658–60.PubMedCrossRef
20.
Zurück zum Zitat Lo Cascio V, Adami S, Tartarotti D, et al. Aberration in vitamin D metabolism during mianserin treatment. Lancet. 1984 Apr 28;1(8383):958–9. Lo Cascio V, Adami S, Tartarotti D, et al. Aberration in vitamin D metabolism during mianserin treatment. Lancet. 1984 Apr 28;1(8383):958–9.
21.
Zurück zum Zitat Demir C, Mousa U, Anil C, et al. Effects of atorvastatin and rosuvastatin therapy on serum 25-hydroxyvitamin D levels: a comparative study. In: Abstracts E, editor. European Congress of Endocrinology 2011; 30 April 2011–04 May 2011. Rotterdam: BioScientifica; 2011. p. P548.1. Demir C, Mousa U, Anil C, et al. Effects of atorvastatin and rosuvastatin therapy on serum 25-hydroxyvitamin D levels: a comparative study. In: Abstracts E, editor. European Congress of Endocrinology 2011; 30 April 2011–04 May 2011. Rotterdam: BioScientifica; 2011. p. P548.1.
22.
Zurück zum Zitat Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25(10):2205–11.PubMedCrossRef Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res. 2010;25(10):2205–11.PubMedCrossRef
23.
Zurück zum Zitat Hansen KE, Jones AN, Lindstrom MJ, Davis LA, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25(12):2786–95. Hansen KE, Jones AN, Lindstrom MJ, Davis LA, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010;25(12):2786–95.
24.
Zurück zum Zitat Sharara AI, El-Halabi MM, Ghaith OA, et al. Proton Pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism. 2012;62(4):518–26.PubMedCrossRef Sharara AI, El-Halabi MM, Ghaith OA, et al. Proton Pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism. 2012;62(4):518–26.PubMedCrossRef
25.
Zurück zum Zitat Sathyapalan T, Shepherd J, Arnett C, et al. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clin Chem. 2010;56(11):1696–700.PubMedCrossRef Sathyapalan T, Shepherd J, Arnett C, et al. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clin Chem. 2010;56(11):1696–700.PubMedCrossRef
26.
Zurück zum Zitat Kos E, Liszek MJ, Emanuele MA, et al. Effect of metformin therapy on vitamin D and vitamin B12 levels in patients with type 2 diabetes mellitus. Endocr Pract. 2012;18(2):179–84. Kos E, Liszek MJ, Emanuele MA, et al. Effect of metformin therapy on vitamin D and vitamin B12 levels in patients with type 2 diabetes mellitus. Endocr Pract. 2012;18(2):179–84.
27.
Zurück zum Zitat Suzuki A, Kotake M, Ono Y, et al. Hypovitaminosis D in type 2 diabetes mellitus: association with microvascular complications and type of treatment. Endocr J. 2006;53(4):503–10.PubMedCrossRef Suzuki A, Kotake M, Ono Y, et al. Hypovitaminosis D in type 2 diabetes mellitus: association with microvascular complications and type of treatment. Endocr J. 2006;53(4):503–10.PubMedCrossRef
28.
Zurück zum Zitat Ragonesi PD, Taddei MT, Ragonesi G, et al. Influence of diabetic treatment regimens on vitamin D metabolism in elderly patients. Arch Gerontol Geriatr. 1996;22(Suppl 1):271–4.PubMedCrossRef Ragonesi PD, Taddei MT, Ragonesi G, et al. Influence of diabetic treatment regimens on vitamin D metabolism in elderly patients. Arch Gerontol Geriatr. 1996;22(Suppl 1):271–4.PubMedCrossRef
29.
Zurück zum Zitat Sato Y, Honda Y, Jun I. Long-term oral anticoagulation therapy and the risk of hip fracture in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Cerebrovasc Dis. 2010;29(1):73–8.PubMedCrossRef Sato Y, Honda Y, Jun I. Long-term oral anticoagulation therapy and the risk of hip fracture in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Cerebrovasc Dis. 2010;29(1):73–8.PubMedCrossRef
30.
Zurück zum Zitat Sato Y, Honda Y, Kunoh H, et al. Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Stroke. 1997;28(12):2390–4.PubMedCrossRef Sato Y, Honda Y, Kunoh H, et al. Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Stroke. 1997;28(12):2390–4.PubMedCrossRef
31.
Zurück zum Zitat Stenova E, Steno B, Killinger Z, et al. Effect of long-term oral anticoagulant therapy on bone mineral density and bone turnover markers: a prospective 12 month study. Bratisl Lek Listy. 2011;112(2):71–6.PubMed Stenova E, Steno B, Killinger Z, et al. Effect of long-term oral anticoagulant therapy on bone mineral density and bone turnover markers: a prospective 12 month study. Bratisl Lek Listy. 2011;112(2):71–6.PubMed
32.
Zurück zum Zitat Prie D, Blanchet FB, Essig M, et al. Dipyridamole decreases renal phosphate leak and augments serum phosphorus in patients with low renal phosphate threshold. J Am Soc Nephrol. 1998;9(7):1264–9.PubMed Prie D, Blanchet FB, Essig M, et al. Dipyridamole decreases renal phosphate leak and augments serum phosphorus in patients with low renal phosphate threshold. J Am Soc Nephrol. 1998;9(7):1264–9.PubMed
33.
Zurück zum Zitat Vestergaard P, Hermann P, Jensen JE, et al. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int. 2012;23(4):1255–65.PubMedCrossRef Vestergaard P, Hermann P, Jensen JE, et al. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int. 2012;23(4):1255–65.PubMedCrossRef
34.
Zurück zum Zitat Cigolini M, Iagulli MP, Miconi V, et al. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2006;29(3):722–4.PubMedCrossRef Cigolini M, Iagulli MP, Miconi V, et al. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2006;29(3):722–4.PubMedCrossRef
35.
Zurück zum Zitat Rejnmark L, Vestergaard P, Pedersen AR, et al. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33(1):41–50.PubMedCrossRef Rejnmark L, Vestergaard P, Pedersen AR, et al. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33(1):41–50.PubMedCrossRef
36.
Zurück zum Zitat Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250(2):144–53.PubMedCrossRef Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of thiazide- and loop-diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study. J Intern Med. 2001;250(2):144–53.PubMedCrossRef
37.
Zurück zum Zitat Reid IR, Ames RW, Orr-Walker BJ, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med. 2000;109(5):362–70.PubMedCrossRef Reid IR, Ames RW, Orr-Walker BJ, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med. 2000;109(5):362–70.PubMedCrossRef
38.
Zurück zum Zitat Insogna KL, Ellison AS, Burtis WJ, et al. Trichlormethiazide and oral phosphate therapy in patients with absorptive hypercalciuria. J Urol. 1989;141(2):269–74.PubMed Insogna KL, Ellison AS, Burtis WJ, et al. Trichlormethiazide and oral phosphate therapy in patients with absorptive hypercalciuria. J Urol. 1989;141(2):269–74.PubMed
39.
Zurück zum Zitat Nowack R, Hofner MC, Reichel H, et al. Subacute effects of thiazide administration on renal hemodynamics and calcium metabolism. Clin Investig. 1992;70(8):686–91.PubMedCrossRef Nowack R, Hofner MC, Reichel H, et al. Subacute effects of thiazide administration on renal hemodynamics and calcium metabolism. Clin Investig. 1992;70(8):686–91.PubMedCrossRef
40.
Zurück zum Zitat Calo L, Cantaro S, Marchini F, et al. Is hydrochlorothiazide-induced hypocalciuria due to inhibition of prostaglandin E2 synthesis? Clin Sci (Lond). 1990;78(3):321–5. Calo L, Cantaro S, Marchini F, et al. Is hydrochlorothiazide-induced hypocalciuria due to inhibition of prostaglandin E2 synthesis? Clin Sci (Lond). 1990;78(3):321–5.
41.
Zurück zum Zitat Krause U, Zielke A, Schmidt-Gayk H, et al. Direct tubular effect on calcium retention by hydrochlorothiazide. J Endocrinol Invest. 1989;12(8):531–5.PubMed Krause U, Zielke A, Schmidt-Gayk H, et al. Direct tubular effect on calcium retention by hydrochlorothiazide. J Endocrinol Invest. 1989;12(8):531–5.PubMed
42.
Zurück zum Zitat Zerwekh JE, Pak CY. Selective effects of thiazide therapy on serum 1 alpha,25-dihydroxyvitamin D and intestinal calcium absorption in renal and absorptive hypercalciurias. Metabolism. 1980;29(1):13–7.PubMedCrossRef Zerwekh JE, Pak CY. Selective effects of thiazide therapy on serum 1 alpha,25-dihydroxyvitamin D and intestinal calcium absorption in renal and absorptive hypercalciurias. Metabolism. 1980;29(1):13–7.PubMedCrossRef
43.
Zurück zum Zitat Laroche M, Mazieres B. Beneficial effect of a thiazide diuretic on bone mineral density in male osteoporosis with hypercalciuria. Clin Exp Rheumatol. 1998;16(1):109–10. Laroche M, Mazieres B. Beneficial effect of a thiazide diuretic on bone mineral density in male osteoporosis with hypercalciuria. Clin Exp Rheumatol. 1998;16(1):109–10.
44.
Zurück zum Zitat Coe FL, Parks JH, Bushinsky DA, et al. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int. 1988;33(6):1140–6.PubMedCrossRef Coe FL, Parks JH, Bushinsky DA, et al. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int. 1988;33(6):1140–6.PubMedCrossRef
45.
Zurück zum Zitat Lemann J Jr, Gray RW, Maierhofer WJ, et al. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int. 1985;28(6):951–8.PubMedCrossRef Lemann J Jr, Gray RW, Maierhofer WJ, et al. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int. 1985;28(6):951–8.PubMedCrossRef
46.
Zurück zum Zitat Dawson-Hughes B, Harris S. Thiazides and seasonal bone change in healthy postmenopausal women. Bone Miner. 1993;21(1):41–51.PubMedCrossRef Dawson-Hughes B, Harris S. Thiazides and seasonal bone change in healthy postmenopausal women. Bone Miner. 1993;21(1):41–51.PubMedCrossRef
47.
Zurück zum Zitat Kokot F, Pietrek J, Srokowska S, et al. 25-hydroxyvitamin D in patients with essential hypertension. Clin Nephrol. 1981;16(4):188–92.PubMed Kokot F, Pietrek J, Srokowska S, et al. 25-hydroxyvitamin D in patients with essential hypertension. Clin Nephrol. 1981;16(4):188–92.PubMed
48.
Zurück zum Zitat Drinka PJ, Krause PF, Nest LJ, et al. Determinants of parathyroid hormone levels in nursing home residents. J Am Med Dir Assoc. 2007;8(5):328–31.PubMedCrossRef Drinka PJ, Krause PF, Nest LJ, et al. Determinants of parathyroid hormone levels in nursing home residents. J Am Med Dir Assoc. 2007;8(5):328–31.PubMedCrossRef
49.
Zurück zum Zitat Sowers MR, Wallace RB, Hollis BW. The relationship of 1,25-dihydroxyvitamin D and radial bone mass. Bone Miner. 1990;10(2):139–48.PubMedCrossRef Sowers MR, Wallace RB, Hollis BW. The relationship of 1,25-dihydroxyvitamin D and radial bone mass. Bone Miner. 1990;10(2):139–48.PubMedCrossRef
50.
Zurück zum Zitat Perry HM 3rd, Jensen J, Kaiser FE, et al. The effects of thiazide diuretics on calcium metabolism in the aged. J Am Geriatr Soc. 1993;41(8):818–22.PubMed Perry HM 3rd, Jensen J, Kaiser FE, et al. The effects of thiazide diuretics on calcium metabolism in the aged. J Am Geriatr Soc. 1993;41(8):818–22.PubMed
51.
Zurück zum Zitat Rejnmark L, Vestergaard P, Heickendorff L, et al. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res. 2006;21(1):163–70.PubMedCrossRef Rejnmark L, Vestergaard P, Heickendorff L, et al. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res. 2006;21(1):163–70.PubMedCrossRef
52.
Zurück zum Zitat Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover. J Intern Med. 2005;257(2):176–84.PubMedCrossRef Rejnmark L, Vestergaard P, Heickendorff L, et al. Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover. J Intern Med. 2005;257(2):176–84.PubMedCrossRef
53.
Zurück zum Zitat Reichel H, Deibert B, Geberth S, et al. Frusemide therapy and intact parathyroid hormone plasma concentrations in chronic renal insufficiency. Nephrol Dial Transplant. 1992;7(1):8–15.PubMed Reichel H, Deibert B, Geberth S, et al. Frusemide therapy and intact parathyroid hormone plasma concentrations in chronic renal insufficiency. Nephrol Dial Transplant. 1992;7(1):8–15.PubMed
54.
Zurück zum Zitat Calo L, Cantaro S, Piccoli A, et al. Effect of nifedipine on urinary excretion of calcium and calcium-controlling hormones in essential hypercalciuria. Cardiovasc Drugs Ther. 1990;4(Suppl 5):983–6.PubMedCrossRef Calo L, Cantaro S, Piccoli A, et al. Effect of nifedipine on urinary excretion of calcium and calcium-controlling hormones in essential hypercalciuria. Cardiovasc Drugs Ther. 1990;4(Suppl 5):983–6.PubMedCrossRef
55.
Zurück zum Zitat Resnick LM, Nicholson JP, Laragh JH. The effects of calcium channel blockade on blood pressure and calcium metabolism. Am J Hypertens. 1989;2(12 Pt 1):927–30.PubMed Resnick LM, Nicholson JP, Laragh JH. The effects of calcium channel blockade on blood pressure and calcium metabolism. Am J Hypertens. 1989;2(12 Pt 1):927–30.PubMed
56.
Zurück zum Zitat Resnick LM, Nicholson JP, Laragh JH. The antihypertensive effects of calcium channel blockade: role of sodium and calcium metabolism. J Cardiovasc Pharmacol. 1988;12(Suppl 6):S114–6.PubMedCrossRef Resnick LM, Nicholson JP, Laragh JH. The antihypertensive effects of calcium channel blockade: role of sodium and calcium metabolism. J Cardiovasc Pharmacol. 1988;12(Suppl 6):S114–6.PubMedCrossRef
57.
Zurück zum Zitat Townsend R, DiPette DJ, Evans RR, et al. Effects of calcium channel blockade on calcium homeostasis in mild to moderate essential hypertension. Am J Med Sci. 1990;300(3):133–7.PubMedCrossRef Townsend R, DiPette DJ, Evans RR, et al. Effects of calcium channel blockade on calcium homeostasis in mild to moderate essential hypertension. Am J Med Sci. 1990;300(3):133–7.PubMedCrossRef
58.
Zurück zum Zitat Hughes GS Jr, Cowart TD, Oexmann MJ, et al. Verapamil-induced natriuretic and diuretic effects: dependency on sodium intake. Clin Pharmacol Ther. 1988;44(4):400–7.PubMedCrossRef Hughes GS Jr, Cowart TD, Oexmann MJ, et al. Verapamil-induced natriuretic and diuretic effects: dependency on sodium intake. Clin Pharmacol Ther. 1988;44(4):400–7.PubMedCrossRef
59.
Zurück zum Zitat Riegel W, Horl WH, Heidland A. Long-term effects of nifedipine on plasma levels of 25 hydroxyvitamin D and 1,25 dihydroxyvitamin D in hypertensive hemodialyzed patients. Klin Wochenschr. 1986;64(24):1291.PubMedCrossRef Riegel W, Horl WH, Heidland A. Long-term effects of nifedipine on plasma levels of 25 hydroxyvitamin D and 1,25 dihydroxyvitamin D in hypertensive hemodialyzed patients. Klin Wochenschr. 1986;64(24):1291.PubMedCrossRef
60.
Zurück zum Zitat Albers MM, Johnson W, Vivian V, et al. Chronic use of the calcium channel blocker nifedipine has no significant effect on bone metabolism in men. Bone. 1991;12(1):39–42.PubMedCrossRef Albers MM, Johnson W, Vivian V, et al. Chronic use of the calcium channel blocker nifedipine has no significant effect on bone metabolism in men. Bone. 1991;12(1):39–42.PubMedCrossRef
61.
Zurück zum Zitat Perez-Castrillon JL, Justo I, Sanz A, et al. Effect of angiotensin converting enzyme inhibitors on 1.25-(OH)2 D levels of hypertensive patients. Relationship with ACE polymorphisms. Horm Metab Res. 2006;38(12):812–6.PubMedCrossRef Perez-Castrillon JL, Justo I, Sanz A, et al. Effect of angiotensin converting enzyme inhibitors on 1.25-(OH)2 D levels of hypertensive patients. Relationship with ACE polymorphisms. Horm Metab Res. 2006;38(12):812–6.PubMedCrossRef
62.
Zurück zum Zitat Perez-Castrillon JL, Silva J, Justo I, et al. Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens. 2003;16(6):453–9.PubMedCrossRef Perez-Castrillon JL, Silva J, Justo I, et al. Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens. 2003;16(6):453–9.PubMedCrossRef
63.
Zurück zum Zitat Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, et al. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007;99(7):903–5.PubMedCrossRef Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, et al. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007;99(7):903–5.PubMedCrossRef
64.
Zurück zum Zitat Doorenbos CR, de Cuba MM, Vogt L, et al. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. J Steroid Biochem Mol Biol. 2012;128(1–2):56–61.PubMedCrossRef Doorenbos CR, de Cuba MM, Vogt L, et al. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. J Steroid Biochem Mol Biol. 2012;128(1–2):56–61.PubMedCrossRef
65.
Zurück zum Zitat Perez-Castrillon JL, De Luis D, Inglada L, et al. Telmisartan effect’s on remodelling bone markers in hypertensive patients. Nutr Hosp. 2012;27(1):276–80. Perez-Castrillon JL, De Luis D, Inglada L, et al. Telmisartan effect’s on remodelling bone markers in hypertensive patients. Nutr Hosp. 2012;27(1):276–80.
67.
Zurück zum Zitat Rejnmark L, Vestergaard P, Heickendorff L, et al. Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol. 2010;2010:957174.PubMedCentralPubMedCrossRef Rejnmark L, Vestergaard P, Heickendorff L, et al. Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol. 2010;2010:957174.PubMedCentralPubMedCrossRef
68.
Zurück zum Zitat Sathyapalan T, Shepherd J, Atkin SL, et al. The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes Obes Metab. 2013;15(8):767–9. Sathyapalan T, Shepherd J, Atkin SL, et al. The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes Obes Metab. 2013;15(8):767–9.
69.
Zurück zum Zitat Liberopoulos EN, Makariou SE, Moutzouri E, et al. Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. J Cardiovasc Pharmacol Ther. 2013;2:1–5. Liberopoulos EN, Makariou SE, Moutzouri E, et al. Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. J Cardiovasc Pharmacol Ther. 2013;2:1–5.
70.
Zurück zum Zitat Ertugrul DT, Yavuz B, Cil H, et al. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovascular Ther. 2011;29(2):146–52. Ertugrul DT, Yavuz B, Cil H, et al. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovascular Ther. 2011;29(2):146–52.
71.
Zurück zum Zitat Ismail F, Corder CN, Epstein S, et al. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin Ther. 1990;12(5):427–30. Ismail F, Corder CN, Epstein S, et al. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin Ther. 1990;12(5):427–30.
72.
Zurück zum Zitat Montagnani M, Lore F, Di Cairano G, et al. Effects of pravastatin treatment on vitamin D metabolites. Clin Ther. 1994;16(5):824–9. Montagnani M, Lore F, Di Cairano G, et al. Effects of pravastatin treatment on vitamin D metabolites. Clin Ther. 1994;16(5):824–9.
73.
Zurück zum Zitat Dobs AS, Levine MA, Margolis S. Effects of pravastatin, a new HMG-CoA reductase inhibitor, on vitamin D synthesis in man. Metabolism. 1991;40(5):524–8.PubMedCrossRef Dobs AS, Levine MA, Margolis S. Effects of pravastatin, a new HMG-CoA reductase inhibitor, on vitamin D synthesis in man. Metabolism. 1991;40(5):524–8.PubMedCrossRef
74.
Zurück zum Zitat Ott C, Raff U, Schneider MP, et al. 25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. Clin Res Cardiol. 2013 ;102(4) :299–304. Ott C, Raff U, Schneider MP, et al. 25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. Clin Res Cardiol. 2013 ;102(4) :299–304.
75.
Zurück zum Zitat Makariou SE, Liberopoulos EN, Agouridis AP, et al. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. J Cardiovasc Pharmacol Ther. 2012;17(4):382–6.PubMedCrossRef Makariou SE, Liberopoulos EN, Agouridis AP, et al. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. J Cardiovasc Pharmacol Ther. 2012;17(4):382–6.PubMedCrossRef
76.
Zurück zum Zitat Yavuz B, Ertugrul DT, Cil H, et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther. 2009;23(4):295–9. Yavuz B, Ertugrul DT, Cil H, et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther. 2009;23(4):295–9.
77.
Zurück zum Zitat Verhoeven V, Vanpuyenbroeck K, Lopez-Hartmann M, et al. Walk on the sunny side of life–epidemiology of hypovitaminosis D and mental health in elderly nursing home residents. J Nutr Health Aging. 2012;16(4):417–20.PubMedCrossRef Verhoeven V, Vanpuyenbroeck K, Lopez-Hartmann M, et al. Walk on the sunny side of life–epidemiology of hypovitaminosis D and mental health in elderly nursing home residents. J Nutr Health Aging. 2012;16(4):417–20.PubMedCrossRef
78.
Zurück zum Zitat Jones G. Metabolism and biomarkers of vitamin D. Scand J Clin Lab Invest Suppl. 2012;243:7–13.PubMed Jones G. Metabolism and biomarkers of vitamin D. Scand J Clin Lab Invest Suppl. 2012;243:7–13.PubMed
79.
Zurück zum Zitat Bugel S, Vitamin K. Vitamin K and bone health in adult humans. Vitam Horm. 2008;78:393–416.PubMedCrossRef Bugel S, Vitamin K. Vitamin K and bone health in adult humans. Vitam Horm. 2008;78:393–416.PubMedCrossRef
80.
Zurück zum Zitat Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687–710.PubMedCrossRef Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687–710.PubMedCrossRef
81.
Zurück zum Zitat Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007;71(2):134–9.PubMedCrossRef Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007;71(2):134–9.PubMedCrossRef
82.
Zurück zum Zitat Gama R, Waldron JL, Ashby HL, et al. Hypovitaminosis D and disease: consequence rather than cause? BMJ. 2012;345:e5706. Gama R, Waldron JL, Ashby HL, et al. Hypovitaminosis D and disease: consequence rather than cause? BMJ. 2012;345:e5706.
83.
Zurück zum Zitat Ding C, Parameswaran V, Blizzard L, et al. Not a simple fat-soluble vitamin: changes in serum 25-(OH)D levels are predicted by adiposity and adipocytokines in older adults. J Intern Med. 2010;268(5):501–10.PubMedCrossRef Ding C, Parameswaran V, Blizzard L, et al. Not a simple fat-soluble vitamin: changes in serum 25-(OH)D levels are predicted by adiposity and adipocytokines in older adults. J Intern Med. 2010;268(5):501–10.PubMedCrossRef
84.
Zurück zum Zitat Querfeld U. Vitamin D and inflammation. Pediatr Nephrol. 2012;28(4):605–10. Querfeld U. Vitamin D and inflammation. Pediatr Nephrol. 2012;28(4):605–10.
85.
Zurück zum Zitat Milaneschi Y, Hoogendijk W, Lips P, et al. The association between low vitamin D and depressive disorders. Mol Psychiatry. Epub 2013 Apr 9. Milaneschi Y, Hoogendijk W, Lips P, et al. The association between low vitamin D and depressive disorders. Mol Psychiatry. Epub 2013 Apr 9.
86.
Zurück zum Zitat Riegel W, Horl WH, Heidland A. Long-term effects of nifedipine on carbohydrate and lipid metabolism in hypertensive hemodialyzed patients. Klin Wochenschr. 1986;64(21):1124–30.PubMedCrossRef Riegel W, Horl WH, Heidland A. Long-term effects of nifedipine on carbohydrate and lipid metabolism in hypertensive hemodialyzed patients. Klin Wochenschr. 1986;64(21):1124–30.PubMedCrossRef
Metadaten
Titel
The Association Between Drugs Frequently Used by the Elderly and Vitamin D Blood Levels: A Review of Observational and Experimental Studies
verfasst von
Anne Claire B. van Orten-Luiten
André Janse
Rosalie A. M. Dhonukshe-Rutten
Renger F. Witkamp
Publikationsdatum
01.02.2014
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 2/2014
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-013-0137-1

Weitere Artikel der Ausgabe 2/2014

Drugs & Aging 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.